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Introduction
Considerable scientific evidence has been published
in recent years (1-17) to show that in the treatment of
malignant and benign thyroid nodular pathologies, to-
tal thyroidectomy (TT) is, in principle, more effective
than near total thyroidectomy (NTT) or subtotal thy-
roidectomy (ST) in terms of:
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Total Thyroidectomy (TT) is a gold standard for benign bilateral
pathologies and malignant pathologies of the thyroid. TT has numerous
advantages over less radical approaches, such as the resolution of the thy-
roid pathology, avoidance of recurrences, and improved response to life-
long substitutive organotherapy. TT has a negligible rate of recurrence.
Near Total Thyroidectomy (NTT) is associated with a low rate of re-
currence. Subtotal Thyroidectomy (ST), in which a portion of the thy-
roid gland is deliberately left in the thyroid lodge, has a considerably hi-
gher rate of recurrence. The incidence of complications with TT is si-
milar to that with other techniques of thyroid exeresis. However, despi-
te the radical intent of surgeons, a real TT is not always carried out.
The complete removal of all the thyroid tissue employing TT is not the
norm and micro/macroscopic remnants almost always remain. The li-
terature on these tissue remnants is often based on techniques that are
not very accurate in terms of determining the diameters of the tissue re-
maining. In our study, conducted by colour echo-doppler of the thyroid
lodge in 102 patients who had undergone TT for benign thyroid patho-
logies, we demonstrated significant thyroid tissue remnants after TT in
34 cases of 102 (33,3%).
Therefore, out of a total of 102 so-called “total thyroidectomies”, only
68 (66,7%) were really total, whereas 12 patients (11,76%) had near
total thyroidectomy, leaving tissue remnants < 1 cm, and 22 patients
(21,57%) had subtotal thyroidectomy, with tissue remnants ≥ 1 cm. 
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La tiroidectomia totale (TT) è il trattamento di scelta per le patolo-
gie benigne bilaterali e patologie maligne della tiroide. TT ha numerosi
vantaggi rispetto ad approcci meno radicali, quali la risoluzione della pa-
tologia tiroidea, l’assenza di recidive, e la buona risposta all’ormonotera-
pia sostitutiva permanente. TT ha un insignificante tasso di recidive. La
tiroidectomia quasi totale (TQT) è associata ad un basso tasso di recidive.
La tiroidectomia subtotale (TS), mediante la quale una porzione di pa-
renchima tiroideo viene deliberatamente lasciata nella loggia tiroidea, è as-
sociata ad un tasso più alto di recidive. L’incidenza delle complicanze del-
la TT è simile a quella delle altre tecniche di exeresi tiroidea. Comunque,
nonostante l’intento radicale dei chirurghi, una reale TT non viene sem-
pre portata a termine. La completa rimozione di tutto il tessuto tiroideo
mediante TT non è la regola e residui micro/macroscopici sono spesso pre-
senti. I lavori della letteratura, riguardo a questo tessuto tiroideo residuo,
hanno spesso impiegato tecniche non del tutto accurate nel determinare il
diametro del tessuto rimanente. Nel nostro studio, condotto mediante eco-
color doppler della loggia tiroidea in 102 pazienti che sono stati sottoposti
a TT per patologie tiroidee benigne, abbiamo dimostrato la presenza di un
significativo residuo di tessuto tiroideo dopo TT in 34 casi su 102 (33,3%). 
Pertanto, su di un totale di 102 cosiddette “tiroidectomie totali”, so-
lo 68 (66,7%) sono risultate realmente totali, mentre in 12 pazienti
(11,76%) è stata eseguita una tiroidectomia quasi totale (TQT), essen-
do il tessuto tiroideo residuo < 1 cm, e in 22 (21,57%) una tiroidecto-
mia subtotale (TS), con tessuto residuo ≥ 1 cm.
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- curing thyroid disease, 
- avoiding recurrences, 
- providing a better response to life-long substitu-
tive organotherapy, 
- allowing the use of thyreoglobulin (Tg) as a
marker of recurrence or metastasis, 
- allowing the use of radioiodine successively for
diagnosis and therapy of any functioning neo-
plastic recurrences found.
Neoplastic thyreocytes maintain the capacity to fix
radioactive iodine under thyreotropinic stimulation; this
capacity, however, is considerably lower than that of nor-
mal thyroid cells (50-100 times less). Adjuvant meta-
bolic radioiodine therapy is possible, therefore, only af-
ter the complete ablation of all the thyroid gland pa-
renchyma. This total removal allows for the detection
of any local or regional neoplastic recurrences or distal
metastases and leads to a substantial improvement in di-
sease progression through the use of radioisotope the-
rapy (18).
TT is defined as the complete removal of visible thy-
roid tissue in the neck and has a negligible rate of re-
currence. Similarly, NTT, which leaves <1 cm of resi-
dual parenchyma, often behind the recurrent laryngeal
nerve (RLN) near Berry’s ligament, is associated with a
low rate of recurrence. On the contrary, ST, in which a
portion of the thyroid gland is deliberately left in the
thyroid lodge, has a considerably higher rate of recur-
rence (15).
Differentiated carcinoma of the thyroid is characte-
rised by disease progression with a low mortality rate;
however, recurrences can appear even years after surgi-
cal treatment and therefore long-term clinical monito-
ring protocols are required (18).
After surgery, attentive monitoring of patients with
thyroid cancer is essential in order to detect local or re-
gional recurrences and to ensure that there are no distal
metastases (17).
According to recently published European and Ame-
rican guidelines, in the treatment of patients with dif-
ferentiated thyroid cancer, ultrasound of the neck to eva-
luate the thyroid lodge and the lymphonode compart-
ments of the neck is recommended at 6 to 12 months
and then annually for at least 3 to 5 years, depending
on the patient’s risk category (1, 2, 17).
The main objectives of the follow-up are the:
- early identification of any signs of disease persi-
stence,
- identification, in the first stage, of recurrences or
metastases,
- monitoring of suppressive doses of levothyroxine.
Careful surveillance in order to identify any recur-
rences in apparently disease-free patients is the primary
objective of long term follow-up. Postoperative evalua-
tions include an objective examination of the neck, thy-
roid and laterocervical colour echo-Doppler, X-ray of the
thorax to show any lung metastases, iodine-131 whole
body scanning (WBS), tumor markers such as thyreo-
globulin (Tg) for carcinomas of thyreocyte genesis, and
calcitonin for medullary thyroid carcinoma (17).
The recurrence of papillary carcinoma in the thyroid
lodge, particularly in elderly patients with extrathyroid
pathology, is associated with a significant increase in the
mortality rate related to cancer (17, 19, 20). Early de-
tection of local/regional recurrences, in patients with in-
vasive pathology is essential to achieve improved thera-
peutic surgical results or metabolic radiotherapy success
(17).
Regarding lesions situated in the thyroid lodge of pa-
tients who had previously undergone thyroidectomy, the
distinction between thyroid cancer recurrence, benign
recurrence and thyroid remnants is not always strai-
ghtforward based solely on ultrasound results, due to the
lack of specific diagnostic criteria.
Cytopathologic examination of fine-needle aspiration
samples or surgical excision of suspect nodes is someti-
mes necessary to determine the histological nature of su-
ch lesions (17).
We carried out colour echo-doppler examinations of
the thyroid lodge in 102 TT patients to demonstrate that
TT does not always correspond with the complete re-
moval of the thyroid gland and that a significant num-
ber of TT cases should be declassified into NTT or ST. 
Patients and methods
A retrospective analysis of patient database of the Department
of Radiological Sciences was conducted to identify all the patients
who had undergone total thyroidectomy for benign thyroid patho-
logies.
During the follow-up, at intervals of 6-12 months, all the pa-
tients were first prescribed: - thyroid hormones, in their free frac-
tion (FT3, FT4); TSH (thyroid-stimulating hormone); thyreoglo-
bulin and/or antithyreoglobulin antibodies during suppressive and/or
substitutive hormonal therapy; colour echo-Doppler of the neck and,
in the case of doubtful ultrasound results, scintigraphy. 
Ultrasound of the neck is recommended to evaluate the thyroid
lodge and the lymphonode compartments at 6 and 12 months, and
then yearly for a period of time that depends on the risk category
of the patient. All the patients in this study underwent an ultrasound
of the neck within a year of surgery. A Technos MPX, Esaote, Ge-
nova, Toshiba Aplio VX, Osaka, Japan, equipped with a high fre-
quency linear probe (7.5-13 MHZ) was used. The examination was
conducted by an expert operator to detect the presence of any resi-
dual thyroid tissue and/or other neck pathologies. When residual thy-
roid tissue was found, at least two diameters were measured and ul-
trastructural and vascularization evaluations were carried out. 
A total of 102 patients were selected who had undergone ul-
trasound examination of the neck during follow-up after total thy-
roidectomies carried out at different Hospitals for benign thyroid
pathologies from January 2004 to December 2007, 12 males and
90 females (ratio M/F = 1/7,5), mean age 57 years (range 18–81
years).
Results
Thyroid gland remnants were found in 33.3% of the
total cases examined (34/102); of these, 32 patients we-
re female and 2 were male M/F = 1/16); the mean age
was 56.9 years (range 34–79 years). Therefore, there we-
re no significant differences in terms of age or sex. The
mean maximum diameter of the gland remnants ob-
served in the thyroid lodge was 10.58 mm (range 4–30
mm).
Of these 34 cases, 22 (64,7%) showed a maximum
diameter of tissue remnants of ≥ 1cm, while in 12 ca-
ses (35.3%), the maximum diameter of gland paren-
chyma was < 1cm.
Therefore, out of a total of 102 TTs, only 68 (66,7%)
were effectively total, whereas 34 (33.3%) were shown
to be less than total; specifically 12 patients of 102
(11.76%), who instead of having undergone a TT, had
had an NTT, leaving parenchyma remnants <1cm; whi-
le 22 (21.57%) patients really underwent an ST, with
tissue remnants ≥1cm.
In 10 of the 34 cases (29.4%) the thyroid parenchyma
remnants were found to be bilateral in the thyroid lod-
ge, while in 24 cases (70.6%) it was unilateral. Of the
latter, 9 cases (37.5%) were on the right and 15 cases
(62.5%) on the left. 
Discussion
TT has numerous advantages over less radical ap-
proaches, such as the resolution of the thyroid patho-
logy, avoidance of recurrences, and improved response
to life-long substitutive organotherapy. TT allows the
use of thyreoglobulin (Tg) as a marker of recurrences
and metastases, and also the subsequent use radioiodi-
ne for diagnosis and treatment of functioning metasta-
ses. Despite the fact that TT as the initial treatment re-
mains controversial, it is nonetheless recommended for
the treatment of the majority of patients with benign
or malignant thyroid pathologies (1, 2, 16).
Although papillary carcinoma has a disease progres-
sion that is not highly aggressive and the mortality ra-
te is not high, recurrences can occur even many years
after surgical treatment (18-21).Recurrence of papillary
carcinoma in the thyroid lodge, particularly in elderly
patients with extrathyroid pathologies, carries a signifi-
cantly increased risk of mortality (17, 22, 23). Early dia-
gnosis of local/regional recurrences in patients with in-
vasive diseases is, therefore, important to achieving grea-
ter surgical therapeutic success and/or more effective ra-
dio-metabolic treatment. Thus, long-term monitoring
protocols are essential with such patients (18).
The extension of TT to benign thyroid pathologies
is still a matter of discussion. The object of surgical treat-
ment is to ensure the best therapeutic treatment with
the lowest possible risk of complications and to avoid
the need to reoperate the neck. TT is the treatment of
choice when the thyroid pathology involves both lobes
and if there is a high risk of recurrence, as in multino-
dal benign goitre, Flaiani-Graves-Basedow disease and
cancer (6, 24, 25). Some surgeons maintain that the mor-
bidity of non-total operations is lower than TT (24, 26,
27); therefore, they generally prefer ST for benign patho-
logies. In agreement with certain authors, TT may be
preferable in order to achieve the complete eradication
of the disease and to prevent recurrences, to facilitate ra-
dioiodine treatment and to eliminate the risk that the
irradiated thyroid can degenerate into a malignant sta-
te (24, 28). Arguments against this strategy are based on
a higher rate of complications, in particular, lesion of
the recurrent nerve and hypoparathyroidism and the
need for life-long substitutive organotherapy (24, 29-
31).
The efficacy of suppressive treatment with L-tiroxina
is still controversial (24, 32-36); substitutive orga-
notherapy in TT patients can be considered as a de-
pendence, but more than half of the patients who un-
dergo Dunhill Procedure (DP) or ST need to take L-ti-
roxina (24). DP is a technique of thyroid removal first
carried out at the beginning of the last century by Sir
Thomas P. Dunhill (1876-1957), who used the proce-
dure for toxic goitre. This procedure consists in the re-
moval of a lobe, the isthmus and from half to two thirds
of the contralateral lobe (24, 37). The term DP was used
with reference to treating Graves’ disease by certain
authors (24, 38, 39).
It has been suggested that TT is a gold standard for
diffuse bilateral pathologies and malign pathologies of
the thyroid. Another factor in favour of TT is the risk
of cancer onset or recurrence in residual thyroid tissue
after NTT (40). The incidence of complications with
TT is similar to that with other techniques of thyroid
exeresis, thus, TT could be adopted for surgical treat-
ment also in cases of benign thyroid pathology. In ad-
dition, reoperation of the neck carries a higher risk of
morbidity; therefore, the authors consider TT to be the
treatment of choice, despite the need for life-long sub-
stitutive organotherapy (24).
TT has a low risk of local/regional recurrence and
facilitates detection of metastases both through serum
Tg assessment and through 131I WBS (13, 14, 16).
Furthermore, TT can improve survival in high-risk pa-
tients without increasing surgical morbidity, if carried
out expertly (41). 
Some authors carry out TT from one side and ST
from the other for benign thyroid pathologies such as
Graves’ disease and nodular goitre (24, 26, 27). It has
been observed that TT is indicated for Graves’ disease
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and that it is as safe as ST (24, 26, 39); Koyuncu et al.
(24) performed TT also for other benign thyroid diseases
(24). 
Pappalardo et al. (42) compared TT and DP during
a long-term follow-up period, and they saw recurrences
in 10 (14%) of 72 patients operated on with ST (24).
Koyuncu et al. (24) compared three different techniques
of thyroid removal: TT, ST and DP. The rate of paralysis
of the RLN with TT compared with ST was 0-1% e 1-
3%, respectively (24, 43-45). The rate of permanent hy-
poparathyroidism with TT compared with ST was 0-
3,8% and 0-0,2% respectively (24, 43, 44). The most
important factor in the prevention of complications with
thyroidectomy is the use of an appropriate surgical te-
chnique; the identification and conservation of the pa-
rathyroid and recurrent laryngeal nerve during surgery
is considered the most valid method of avoiding more
serious complications. Routine identification and con-
servation of these organs and their vascularization leads
to a reduction of complications to the minimum (24).
The study of Koyuncu et al. (24) did not show any per-
manent paralysis of the RLN in any of the 3 groups.
It is a common opinion that, despite the radical in-
tent of surgeons, a real TT is rarely carried out. Rem-
nants of thyroid tissue are often found and usually treat-
ment with radioiodine (RAI, 131I) is necessary for the
complete ablation of the remaining material (16, 46). 
The literature on these tissue remnants is not very
recent and is often based on techniques that are not very
accurate in terms of determining the diameters of the
tissue remaining (16, 47-49).
The first study in this area was in 1942 when
Reinhardt employed autoradiography with 131I and ob-
served thyroid tissue remnants in 7 of 12 rats that had
undergone TT (16, 50). After this initial research, nu-
merous clinical studies almost always demonstrated the
presence of functioning thyroid tissue after TT, so mu-
ch so that in certain centres, after ablative surgical treat-
ment, therapy with radioiodine was carried out without
a preliminary WBS (16, 50-52). The study of Salvato-
ri et al. (16) showed that in 93.1% of TT, some residual
thyroid tissue remains. In fact, these authors showed that
only 6.9% of patients were clear of thyroid tissue after
TT; 381 patients had residual thyroid tissue inside and
236 outside of the tumoural bed. The criteria defining
the success of a thyroid ablation specify the complete re-
moval of every visible functioning area in the thyroid
lodge, a 24-h 131I quantitative neck uptake (RAIU test)
lower than 1% and a serum Tg off LT4 (serum Tg le-
vels measured after L-T4 withdrawal; TSH > 30 µUI/ml)
less than 2 ng/ml in the absence of Tg Ab. That study
showed that many patients had thyroid remnants con-
tralaterally of the affected lobe, demonstrating that at-
tention is focused primarily of the diseased lobe in the
case of unilateral pathology (16).
In the present study, we found significant levels of
thyroid tissue remnants after TT in 34 cases of 102
(33.3%). Ultrasound evaluation of the neck showed 12
cases (11.7%), which should be re-classified as NTT
(remnants < 1 cm), and 22 (21.6%) as ST (remnants 
≥ 1 cm); thyroid remnants as large as 3 cm of parenchyma
were observed (range 0.4-30 mm).
The 6.9 % of effective TT found by Salvatori et al.
(16) is not excessively low considering that the authors
evaluated the presence or absence of thyroid remnants
using the most accurate qualitative and quantitative dia-
gnostic available and they established a strict cut-off va-
lue and highly specific criteria to define thyroid remnants.
In particular, they scanned the neck using therapeutic
doses of radioiodine; a very accurate diagnostic method
to detect thyroid remnants due to the high photon stream
and the consequent elevated thyroid remnant to the back-
ground radioactivity ratio (16, 53). This 6.9% of patients
without thyroid remnants, which was considered high
by the authors, could be explained by the fact that they
decided to evaluate only patients operated on by surgeons
expert in endocrinology (16).
Sosa et al. (54) demonstrated that the individual ex-
perience of the surgeon was significantly associated with
the rate of post-thyroidectomy complications and the
duration of postoperative hospitalization. He found a
relationship between the experience of the surgeon and
postoperative clinical progression in thyroid surgery. It
is not surprising that the expertise of the surgeon can
influence the percentage and the diameters of thyroid
tissue remnants after TT (16).
In patients with thyroid tissue remnants, analysis of
the distribution of 131I has shown that a significant num-
ber of functioning tissue foci situated at the extreme su-
perior pole and in the pyramidal lobe, and these results
could be explained by anatomical and pathophysiolo-
gical reasons (16). Fratkin et al. (55) demonstrated that
an area of difficulty for surgeons is Berry’s ligament, a
small, dense portion of the mid-posterior area of the thy-
roid capsule, which in any case is rather variable. This
ligament links the thyroid tightly to the antero-lateral
face of the trachea; the RLN runs inside this ligament
for a few millimetres. Thus, in an attempt to avoid da-
maging this nerve, incomplete resection of the thyroid
gland in this area may result in foci of 131I uptake in po-
stoperative scans.
In conclusion, TT is the surgical intervention of choi-
ce in malignant thyreopathologies and also in diffuse be-
nign diseases affecting both lobes. It leads to a percen-
tage of complications similar to NTT and ST, therefo-
re, in our opinion, it represents the gold standard not
only for malignant thyroid pathologies, but also for the
majority of benign thyroid diseases. When carried out
in specialized centres for thyroid surgery, the rate of com-
plications is low. However, the complete removal of all
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the thyroid tissue employing TT is not the norm and
micro/macroscopic remnants almost always remain (47,
48). 
All patients undergoing TT, and not only those ope-
rated on for cancer of the thyroid, should be re-exami-
ned 6 months after the operation with a colour echo-
doppler of the thyroid lodge and reclassified on the ba-
sis of tissue remnants as follows:
A) Total Thyroidectomy (TT) = absence of macro-
scopic thyroid tissue remnants;
B) Near Total Thyroidectomy (NTT) = presence of
thyroid tissue remnants < 1 cm;
C) Subtotal Thyroidectomy (ST) = presence of thy-
roid tissue remnants ≥ 1 cm. 
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